	US 12,239,673 B2
	Composition comprising pediococcus pentosaceus for use in treatment and/or prevention of food and/or alcohol poisoning
Eric Beaussant Törne, Tyresö (SE); and Evaggelos Schjölin, Tyresö (SE)
Appl. No. 18/555,515
Filed by Evaggelos Schjölin, Tyresö (SE)
PCT Filed Aug. 11, 2022, PCT No. PCT/EP2022/072523 § 371(c)(1), (2) Date Oct. 14, 2023, PCT Pub. No. WO2023/030850, PCT Pub. Date Mar. 9, 2023.
Claims priority of application No. 2151087-0 (SE), filed on Aug. 31, 2021; application No. 2151493-0 (SE), filed on Dec. 7, 2021; and application No. 2151496-3 (SE), filed on Dec. 8, 2021.
Prior Publication US 2024/0189370 A1, Jun. 13, 2024
Int. Cl. A61K 35/744 (2015.01); A61K 36/064 (2006.01); A61P 25/32 (2006.01)

CPC A61K 35/744 (2013.01) [A61K 36/064 (2013.01); A61P 25/32 (2018.01)]

16 Claims

1. A composition comprising

0.1 to 5 wt %, 10³to 10¹¹CFU/g Pediococcus Pentosaceus, wherein P. pentosaceus is the sole bacterium in the composition,

1 to 50 wt % at 10⁵to 10¹⁵CFU/g one or more yeast, which is any brewer's yeast or Saccharomyces cerevisiae, wherein the weight ratio of Pediococcus Pentosaceus:yeast is between 0.01 to 0.1:1,

1 to 80 wt % one or more minerals, and one or more pharmaceutical acceptable excipients, additives and/or adjuvants, and

optionally 1 to 40 wt % sugar,

wherein the composition is in the form of a pharmaceutically acceptable tablet or capsule.